Feature | November 19, 2013

AtriCure Receives FDA Go-Ahead for Investigational Study for LAA Occluder

AtriClip Left Atrial Appendage Exclusion System to be evaluated as alternative to anticoagulation therapy

laa occluders structural heart atrial fibrillation atricure atriclip exclusion
November 19, 2013 — AtriCure Inc., a developer of solutions to treat atrial fibrillation, announced the U.S. Food and Drug Administration’s (FDA’s) approval to begin enrollment in a clinical study of AtriCure’s AtriClip Left Atrial Appendage Exclusion System. The study will evaluate the use of the AtriClip device to prevent stroke in patients with atrial fibrillation.
 
The feasibility study will enroll Atrial fibrillation patients at seven medical centers across the country. The study will focus on patients with risk factors that place them at significant risk of stroke as well as substantial bleeding risks that contraindicate them for anticoagulation therapy. Research suggests that up to 40 percent of patients are unable to take oral anticoagulants due to excessive risk of bleeding [1].
 
Patients with Atrial fibrillation have a 500 percent increased risk of stroke over the general public [2]. Atrial fibrillation related strokes are associated with higher morbidity and mortality than non-Atrial fibrillation related strokes [3]. Since the left atrial appendage (LAA), a muscular pouch attached to the heart, has been found to be the source of approximately 90 percent of thrombi in Atrial fibrillation patients evaluated after a confirmed stroke, this study will focus on complete and permanent mechanical closure of the LAA [4].
 
During the feasibility study, patients will undergo a minimally invasive surgical procedure. Utilizing small incisions in the chest wall surgeons will place the AtriClip device directly onto the base of the LAA while the heart is still beating. Complete exclusion of the LAA is confirmed during the procedure using echo graphic imaging. Three months following the procedure, a computed tomography (CT) scan will be performed to re-confirm complete and permanent LAA exclusion on all patients.
 
The AtriClip LAA Exclusion System is indicated for the occlusion of the LAA, under direct visualization, in conjunction with other open cardiac surgical procedures. AtriCure received FDA 510(k) clearance for the AtriClip device in June 2010 based upon the successful results of the EXCLUDE trial (number G080095). In this study, complete and permanent exclusion of the LAA was confirmed in 98.4 percent of patients by a three-month post procedure CT scan with zero complications or adverse events. Since launch, more than 25,000 AtriClips have been implanted worldwide.
 
“Managing high risk Afib (atrial fibrillation) patients requires balancing the risk of stroke against the risk of major bleeding,” said Basel Ramlawi, M.D., M.M.Sc., cardiothoracic surgeon, Houston Methodist DeBakey Heart Center and the principal investigator in the study. “This study is a major step toward developing the clinical evidence necessary to establish a viable, safe and attractive alternative to lifelong anticoagulation in Afib patients that currently have very limited options. This will have a favorable impact on patients and the healthcare system overall.”
 
“The Stroke Feasibility IDE (investigational device exemption) study is significant because it is the first of its kind to focus entirely on a group of untreated and undertreated Afib patients that may benefit the most from total and permanent exclusion of their left atrial appendage,” said Michael Carrel, president and CEO, AtriCure. “This study is one of three FDA trials that AtriCure is currently running as part of our strategy to be the leader in developing proven and effective solutions for the worldwide Afib epidemic.”
 
For more information: www.atricure.com, www.ncbi.nlm.nih.gov
 
References:
[1] Sudlow M, Thomson R, Thwaites B, Rodgers H, Kenny RA. Prevalence of atrial fibrillation and eligibility of anticoagulation in the community. The Lancet. 1998 Oct 10;352(9135):1167-71.
[2] Benjamin EJ, Chen PS, Bild DE, et al. Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop.Circulation. 2009 Feb 3; 119(4):606-18.
[3] Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005 Jun;36(6):1115-9.
[4] Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Annals of Thoracic Surgery. 1996 Feb:61(2);755-9.

Related Content

AtriCure's AtriClip System Surpasses 100,000 Units Sold Worldwide
News | Left Atrial Appendage (LAA) Occluders| April 25, 2017
AtriCure Inc. announced it has sold more than 100,000 AtriClip Left Atrial Appendage Exclusion System devices worldwide...
Alabama Medical Center First in Southeast to Offer CoreValve Evolut Pro TAVR Device
News | Heart Valve Technology| April 20, 2017
The Structural Heart Program at Princeton Baptist Medical Center, (Birmingham, Ala.) recently became the first center...
CSI recall for saline pump on its atherectomy system
News | Atherectomy Devices| April 19, 2017
Cardiovascular Systems Inc. (CSI) announced April 18 it had initiated a voluntary recall of its 7-10014 Saline Infusion...
Louisiana Medical Center Installs First U.S. Toshiba Medical Infinix-i Sky +
News | Angiography| April 18, 2017
April 18, 2017 — Patients at Terrebonne General Medical Center (TGMC) in Houma, La., now have access to safe, high-qu
Study Finds Significant Variability in Doctors Angioplasty Death Rates
News | Cath Lab| April 17, 2017
Some doctors have higher or lower than expected death rates from coronary angioplasty procedures, also known as...
Sponsored Content | Videos | Ventricular Assist Devices (VAD)| April 14, 2017
A discussion with William O'Neill, M.D., FACC, FSCAI, medical director of the Center for Structural Heart Disease at
An electrophysiology EP ablation procedure to treat a heart arrhythmia
Feature | HRS| April 14, 2017
April 14, 2017 — The Heart Rhythm Society (HRS) has announced its late-breaking clinical trials at its annual meeting
Vascular Dynamics Completes $10.4 Million Financing for MobiusHD System
News | Hypertension| April 13, 2017
Vascular Dynamics Inc. (VDI) a privately held medical device company developing novel solutions for the treatment of...
New Study Pursues Universal Sample Bank for Troponin Tests
News | Blood Testing| April 13, 2017
April 13, 2017 — A study published recently in the American Association for Clinical Chemistry’s (AACC)...
Overlay Init